1. <dd id="1wpvg"></dd>

    <tbody id="1wpvg"><track id="1wpvg"></track></tbody>

  2. <nav id="1wpvg"><big id="1wpvg"><noframes id="1wpvg"></noframes></big></nav><form id="1wpvg"><tr id="1wpvg"><u id="1wpvg"></u></tr></form>

      1. <dd id="1wpvg"><optgroup id="1wpvg"><video id="1wpvg"></video></optgroup></dd>

        <rp id="1wpvg"></rp>



        Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products

        constitutes a patent infringement. The current list only reflects the products and technologies that are available,

        under development: note that some products may be developed or produced for internal and experimental uses

        with no commercal aim.


        Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and

        development quantities.


        the buyer assumes responsibility of all patent considerations in the use of
        Chemieliva Pharmaceutical Co., Ltd product(s).

        Acinopeptide Co., Ltd

        Pharmten Chemical Co., Ltd


        R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law

        in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of

        the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of

        Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of s

        ame by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become

        applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other